137 related articles for article (PubMed ID: 38335691)
1. Insensitivity of oncogenic EGFR R776L mutation to EGFR inhibitors in lung cancer.
Wang Y; Hu C; Yu H; Hu J; Zhou Z; Fu N; Huang X; Kong F; Wang W; Liu J
Lung Cancer; 2024 Mar; 189():107495. PubMed ID: 38335691
[TBL] [Abstract][Full Text] [Related]
2. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract][Full Text] [Related]
3. Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report.
Ren KH; Qin WW; Wang Y; Peng JC; Hu WX
Ann Palliat Med; 2022 Jul; 11(7):2503-2509. PubMed ID: 35927783
[TBL] [Abstract][Full Text] [Related]
4. Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01).
Uryu K; Imamura Y; Shimoyama R; Mase T; Fujimura Y; Hayashi M; Ohtaki M; Otani K; Hibino M; Horiuchi S; Fukui T; Fukai R; Chihara Y; Iwase A; Yamada N; Tamura Y; Harada H; Shinozaki N; Tsuya A; Fukuoka M; Minami H
Jpn J Clin Oncol; 2024 Mar; 54(3):319-328. PubMed ID: 37997468
[TBL] [Abstract][Full Text] [Related]
5. EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.
Saxon JA; Sholl LM; Jänne PA
J Thorac Oncol; 2017 May; 12(5):884-889. PubMed ID: 28088511
[TBL] [Abstract][Full Text] [Related]
6. [Targeted Therapy and Mechanism of Drug Resistance in Non-small Cell Lung Cancer
with Epidermal Growth Factor Receptor Gene Mutation].
Huang J; Wang H
Zhongguo Fei Ai Za Zhi; 2022 Mar; 25(3):183-192. PubMed ID: 35340161
[TBL] [Abstract][Full Text] [Related]
7. Aumolertinib: A Review in Non-Small Cell Lung Cancer.
Shirley M; Keam SJ
Drugs; 2022 Apr; 82(5):577-584. PubMed ID: 35305259
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
9. Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies.
Cortiula F; Pelizzari G; Corvaja C; De Maglio G; Fasola G
Anticancer Drugs; 2022 Oct; 33(9):960-962. PubMed ID: 35979997
[TBL] [Abstract][Full Text] [Related]
10. De Novo mutation in Epidermal growth factor receptor (EGFR)-D761Y responding to third generation tyrosine kinase inhibitor Osimertinib: A case report.
Ding Y; Dong H; Li Y; Liu L; Cai Y; Wang Y; Tian S; Dai C
Medicine (Baltimore); 2022 Jul; 101(29):e29332. PubMed ID: 35866776
[TBL] [Abstract][Full Text] [Related]
11. Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences.
Chen L; Zhou Y; Gan C; Wang X; Liu Y; Dong C; He R; Yang J
Cancer Invest; 2022 Aug; 40(7):590-603. PubMed ID: 35445633
[TBL] [Abstract][Full Text] [Related]
12. Sequential use of EGFR-tyrosine kinase inhibitors based upon EGFR mutation evolution achieves long-term control in a non-small cell lung cancer patient: a case report.
Jiang Y; Zhang J; Jiang X; Cheng L; Liao X; Li Y; Zhang M; Chen R; Yin T
Ann Palliat Med; 2021 Jun; 10(6):7051-7056. PubMed ID: 33548986
[TBL] [Abstract][Full Text] [Related]
13. Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study.
Zhu L; Zou C; Zhang Z; Wang J; Yang L; Rao C; Yang Z; Liang J; Xia B; Shenglin MA
BMC Cancer; 2021 May; 21(1):511. PubMed ID: 33962566
[TBL] [Abstract][Full Text] [Related]
14. Savolitinib monotherapy exerted significant benefit in a non-small cell lung cancer patient with osimertinib resistance harboring primary EGFR L858R mutation and MET amplification: a case report.
Ma P; Huang R; Gu Y; Fang Y; Wu X; Chen DS; Zhang HW; Gao W; Shu Y
Anticancer Drugs; 2022 Nov; 33(10):1186-1190. PubMed ID: 35946569
[TBL] [Abstract][Full Text] [Related]
15. Lipocalin 2 (LCN2) confers acquired resistance to almonertinib in NSCLC through LCN2-MMP-9 signaling pathway.
Shi C; Wang C; Fu Z; Liu J; Zhou Y; Cheng B; Zhang C; Li S; Zhang Y
Pharmacol Res; 2024 Mar; 201():107088. PubMed ID: 38295916
[TBL] [Abstract][Full Text] [Related]
16. Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.
Uchibori K; Inase N; Nishio M; Fujita N; Katayama R
J Thorac Oncol; 2018 Jul; 13(7):915-925. PubMed ID: 29702287
[TBL] [Abstract][Full Text] [Related]
17. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
Lu S; Shih JY; Jang TW; Liam CK; Yu Y
Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350
[TBL] [Abstract][Full Text] [Related]
18. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
19. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
20. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
